This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the Asthma and Allergy Foundation of America (AAFA)

ACKNOWLEDGEMENT

This activity is supported by an educational grant from AstraZeneca.

DATE OF RELEASE/EXPIRATION

This activity was released on August 23, 2022 and is valid until August 23, 2023. Requests for credit must be made no later than August 23 2023

TARGET AUDIENCE

The target audiences for the proposed HCP activity are immunologists, allergists, primary care providers, pediatricians, specialty and non-specialty NPs and PAs, pharmacists, and other members of the multi-disciplinary care team

STATEMENT OF NEED/PROGRAM OVERVIEW

The development of modern biological therapies has revolutionized severe asthma management, but a subset of asthma patients remains symptomatic with poor quality of life and heavy healthcare use. New insights into the role of TSLP in asthma have led to the development of a novel therapy that targets the underlying drivers of inflammation and may alleviate some of this burden on patients.

Join an expert panel of clinicians and patient representatives to review the roles of the various inflammatory pathways in severe asthma, along with the mechanisms of action of various therapies, their safety and efficacy data, and how a new treatment option targeting TSLP can be integrated into the asthma-management armamentarium. Panelists will share strategies to effectively identify those patients most likely to benefit from current and emerging therapies and then select the most appropriate biologic for each patient with severe asthma.

Do you have patients with asthma who could benefit from related education on current and future therapies to reduce exacerbations and gain control of their symptoms? Direct your patients to MedLive.com to access the patient-education activity, “Breathe Easier with Asthma.”

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

• Identify how epithelial alarmins impact T2 and non-T2 downstream inflammation in asthma
• Differentiate the mechanisms of action of available biologics for severe asthma
• Summarize efficacy and safety data related to alarmin blockade with biologic therapy against TSLP
• Identify which patients could benefit from treatment that targets TSLP

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 60 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Name of Faculty or Presenter	Reported Financial Relationship
Jonathan Corren, MD Department of Medicine and Pediatrics, David Geffen School of Medicine at UCLA, University of California	Consulting Fee (e.g., Advisory Board): AstraZeneca, Regeneron, Sanofi Contracted Research: Amgen, AstraZeneca, Novartis, OptiNose, Regeneron, Sanofi,Teva Speakers Bureau: AstraZeneca,Amgen Regeneron, Sanofi
Michael Wechsler, MD Director of The Cohen Family Asthma Institute National Jewish Health	Consulting Fee (e.g., Advisory Board): Amgen, AstraZeneca, Avalo Therapeutics, Boehringer Ingelheim, Cerecor, Cohero Health, Cytoreason Eli Lilly, Equillium, Glaxosmithkline, Incyte, Kinaset Novartis, Om Pharma, Phylaxis, Pulmatrix Rapt Therapeutics, Regeneron, Restorbio Roche/Genentech, Sanofi/Genzyme, Sentien Sound Biologics, Tetherex Pharmaceuticals Teva. Upstream Bio Honoraria: AstraZeneca, GSK, Sanofi, Regeneron
Sanaz Eftekhari Vice President, Corporate Affairs and Research Asthma and Allergy Foundation of America	Nothing to disclose

The planners and managers have the following relevant financial relationships with ineligible companies:

Name of Planner	Reported Financial Relationship
Lindsay Borvansky	Nothing to disclose
Andrea Funk	Nothing to disclose
Liddy Knight	Nothing to disclose
Ashley Cann	Nothing to disclose
Lauren Sinclair	Nothing to disclose
Carole Drexel	Nothing to disclose
Eve Wilson	Nothing to disclose
Caroline Laurendeau	Nothing to disclose

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com

Technical Support:

For any technical issues or issues with your CME Certificate, please contact ImmunologyLive at 877-394-1306 or at Support@ImmunologyLive.com.